Research analysts at LADENBURG THALM/SH SH assumed coverage on shares of Autonomix Medical (NASDAQ:AMIX – Get Free Report) in a research note issued to investors on Tuesday, Benzinga reports. The brokerage set a “buy” rating and a $1.40 price target on the stock. LADENBURG THALM/SH SH’s price target indicates a potential upside of 53.58% from the stock’s previous close.
Autonomix Medical Stock Up 25.4 %
Shares of NASDAQ:AMIX opened at $0.91 on Tuesday. The company has a quick ratio of 9.27, a current ratio of 9.27 and a debt-to-equity ratio of 0.20. The stock’s 50-day moving average is $0.83 and its 200-day moving average is $2.07. Autonomix Medical has a 52-week low of $0.51 and a 52-week high of $7.60.
Autonomix Medical (NASDAQ:AMIX – Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter.
Autonomix Medical Company Profile
Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals.
Featured Articles
- Five stocks we like better than Autonomix Medical
- Consumer Staples Stocks, Explained
- Why Dick’s Could Be a Slam Dunk for Your Investment Portfolio
- CD Calculator: Certificate of Deposit Calculator
- Introduction to Fibonacci Retracement Levels
- The 3 Best Fintech Stocks to Buy Now
- Top 3 Stocks to Outperform the S&P 500 in a Downturn
Receive News & Ratings for Autonomix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autonomix Medical and related companies with MarketBeat.com's FREE daily email newsletter.
